Abstract
Introduction: Cardiac electrophysiological study (EPS) and radiofrequency ablation (RFA) is an established mode of treatment either as first-line or for drug-refractory arrhythmias. Our center has recently started this service under 2-D mapping outside Kathmandu valley
 Objective: The aim was to evaluate the safety and efficacy of EPS and RFA for paroxysmal supraventricular tachycardias (PSVT).
 Methodology: This is an observational prospective study carried out in the Cardiac Unit of Nobel medical college, Biratnagar, Nepal. All cases diagnosed to have PSVT based on electrocardiogram or Holter recordingfromAugust 2018 and May2019wereincluded in the study. Data on clinical profile and findings of EPS were recorded. Fifty-nine cases were chosen for safety and efficacy analysis, using SPSS statistical software version 19.
 Results: There were 59 patients, 28(47.5%) males, and 31(52.5%) females. The mean age was 38.2 ± 15.9 years. Fifty-three patients underwent RFA while 6 patients underwent only EPS. In the Atrioventricular nodal reentry tachycardia (AVNRT) group, there was female dominance (P=0.2) while in Atrioventricular reentry tachycardia (AVRT) group, there was no significant gender difference (p=0.4). Left-sided pathway (68%) was more common in the AVRT group. Among the left accessory pathway (AP), left lateral AP (44%) was more common. No major complications including death were noted. Two cases of successful ablation relapsed in one month follow up.
 Conclusions: Early results of this small study in patients with PSVT confirm the efficacy and safety of RFA in newly established electrophysiology (EP) laboratory.
Highlights
Paroxysmal supraventricular tachycardia (PSVT) is a common problem with a prevalence of approximately 1-3 cases per 1000 persons.1Radiofrequency abla on (RFA) has markedly changed the management of tachyarrhythmias
The first radiofrequency abla on (RFA) of SVT was performed in 1987 and it was started in Nepal since 2003.5 It has been established as the cura ve therapy for most of the PSVT
PSVT was confirmed based on ECG or Holter recording by a trained cardiologist based on their characteris cs, including rapid onset, heart rates of 150 to 250 beats per minute, and regularity of the ventricular response.[7]
Summary
Paroxysmal supraventricular tachycardia (PSVT) is a common problem with a prevalence of approximately 1-3 cases per 1000 persons.1Radiofrequency abla on (RFA) has markedly changed the management of tachyarrhythmias. Current RFA systems permit the temperature control, provide informa on about the adequacy of ssue hea ng and minimize the injury to surrounding ssues.[3] RFA is an established modality in the treatment of supraventricular or ventricular arrhythmias as first-line therapy.[4] The first RFA of SVT was performed in 1987 and it was started in Nepal since 2003.5 It has been established as the cura ve therapy for most of the PSVT. The study aimed to evaluate the efficacy and safety of EPS and RFA in pa ents with PSVT in our newly established electrophysiology laboratory outside Kathmandu valley
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
